These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 23480866)
1. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals. Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075 [TBL] [Abstract][Full Text] [Related]
3. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database. Beninger P; Murray M Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449 [TBL] [Abstract][Full Text] [Related]
4. Differences between the United States and Japan in labels of oncological drugs. Jayaputra K; Ono S Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850 [TBL] [Abstract][Full Text] [Related]
5. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration. Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347 [TBL] [Abstract][Full Text] [Related]
6. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. Yeh JS; Sarpatwari A; Kesselheim AS Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800 [TBL] [Abstract][Full Text] [Related]
7. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967 [TBL] [Abstract][Full Text] [Related]
8. New and incremental FDA black box warnings from 2008 to 2015. Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916 [TBL] [Abstract][Full Text] [Related]
9. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461 [TBL] [Abstract][Full Text] [Related]
10. FDA boxed warnings: how to prescribe drugs safely. O'Connor NR Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888 [TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Arabyat RM; Raisch DW; McKoy JM; Bennett CL Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database. Yavne Y; Amar Shamir R; Shapiro M; Shepshelovich D Expert Opin Drug Saf; 2023; 22(6):463-468. PubMed ID: 36683587 [TBL] [Abstract][Full Text] [Related]
13. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848 [TBL] [Abstract][Full Text] [Related]
14. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988 [TBL] [Abstract][Full Text] [Related]
15. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110 [TBL] [Abstract][Full Text] [Related]
16. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis. Zhou Z; Hultgren KE JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889 [TBL] [Abstract][Full Text] [Related]
17. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896 [TBL] [Abstract][Full Text] [Related]
19. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Wysowski DK; Swartz L Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284 [TBL] [Abstract][Full Text] [Related]
20. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility. Matlock A; Allan N; Wills B; Kang C; Leikin JB Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]